Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye

PHASE4CompletedINTERVENTIONAL
Enrollment

1,049

Participants

Timeline

Start Date

March 4, 2014

Primary Completion Date

June 15, 2016

Study Completion Date

June 15, 2016

Conditions
Wet Age Related Macular Degeneration
Interventions
DRUG

ranibizumab

All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).

Trial Locations (101)

10122

Novartis Investigative Site, Torino

10152

Novartis Investigative Site, Torino

10153

Novartis Investigative Site, Torino

12073

Novartis Investigative Site, Ceva

12100

Novartis Investigative Site, Cuneo

15033

Novartis Investigative Site, Casale Monferrato

15100

Novartis Investigative Site, Alessandria

16035

Novartis Investigative Site, Rapallo

16132

Novartis Investigative Site, Genova

16153

Novartis Investigative Site, Genova

17100

Novartis Investigative Site, Savona

19038

Novartis Investigative Site, Sarzana

20025

Novartis Investigative Site, Legnano

20070

Novartis Investigative Site, Vizzolo Predabissi

20089

Novartis Investigative Site, Rozzano

20092

Novartis Investigative Site, Cinisello Balsamo

20100

Novartis Investigative Site, Milan

20122

Novartis Investigative Site, Milan

20123

Novartis Investigative Site, Milan

20132

Novartis Investigative Site, Milan

20142

Novartis Investigative Site, Milan

21019

Novartis Investigative Site, Somma Lombardo

21052

Novartis Investigative Site, Busto Arsizio

21100

Novartis Investigative Site, Varese

22020

Novartis Investigative Site, San Feramo Della Battaglia

22100

Novartis Investigative Site, Como

23100

Novartis Investigative Site, Sondrio

24127

Novartis Investigative Site, Bergamo

25015

Novartis Investigative Site, Desenzano del Garda

25123

Novartis Investigative Site, Brescia

27100

Novartis Investigative Site, Pavia

28021

Novartis Investigative Site, Borgomanero

28066

Novartis Investigative Site, Galliate

29100

Novartis Investigative Site, Piacenza

31015

Novartis Investigative Site, Conegliano

31100

Novartis Investigative Site, Treviso

32100

Novartis Investigative Site, Belluno

33100

Novartis Investigative Site, Udine

33170

Novartis Investigative Site, Pordenone

34129

Novartis Investigative Site, Trieste

35012

Novartis Investigative Site, Camposampiero

35043

Novartis Investigative Site, Monselice

35100

Novartis Investigative Site, Padua

35128

Novartis Investigative Site, Padua

36014

Novartis Investigative Site, Santorso

36100

Novartis Investigative Site, Vicenza

37024

Novartis Investigative Site, Negrar

37045

Novartis Investigative Site, Legnago

37126

Novartis Investigative Site, Verona

39100

Novartis Investigative Site, Bolzano

40138

Novartis Investigative Site, Bologna

42015

Novartis Investigative Site, Correggio

42123

Novartis Investigative Site, Reggio Emilia

43100

Novartis Investigative Site, Parma

44100

Novartis Investigative Site, Cona

47100

Novartis Investigative Site, Forlì

47838

Novartis Investigative Site, Riccione

60126

Novartis Investigative Site, Ancona

64100

Novartis Investigative Site, Teramo

65124

Novartis Investigative Site, Pescara

66100

Novartis Investigative Site, Chieti

70017

Novartis Investigative Site, Putignano

70021

Novartis Investigative Site, Acquaviva delle Fonti

70038

Novartis Investigative Site, Terlizzi

71013

Novartis Investigative Site, San Giovanni Rotondo

71100

Novartis Investigative Site, Foggia

73039

Novartis Investigative Site, Tricase

74100

Novartis Investigative Site, Taranto

80078

Novartis Investigative Site, Pozzuoli

80131

Novartis Investigative Site, Napoli

80132

Novartis Investigative Site, Napoli

80138

Novartis Investigative Site, Napoli

81100

Novartis Investigative Site, Caserta

84025

Novartis Investigative Site, Eboli

84131

Novartis Investigative Site, Salerno

88074

Novartis Investigative Site, Crotone

88100

Novartis Investigative Site, Catanzaro

89124

Novartis Investigative Site, Reggio Calabria

90127

Novartis Investigative Site, Palermo

90146

Novartis Investigative Site, Palermo

95024

Novartis Investigative Site, Acireale

95123

Novartis Investigative Site, Catania

95124

Novartis Investigative Site, Catania

98057

Novartis Investigative Site, Milazzo

98125

Novartis Investigative Site, Messina

09124

Novartis Investigative Site, Cagliari

Unknown

Novartis Investigative Site, Larino

04019

Novartis Investigative Site, Terracina

08100

Novartis Investigative Site, Nuoro

06012

Novartis Investigative Site, Città di Castello

06034

Novartis Investigative Site, Foligno

06100

Novartis Investigative Site, Perugia

00053

Novartis Investigative Site, Civitavecchia

00133

Novartis Investigative Site, Roma

00161

Novartis Investigative Site, Roma

00168

Novartis Investigative Site, Roma

00184

Novartis Investigative Site, Roma

00186

Novartis Investigative Site, Roma

00189

Novartis Investigative Site, Roma

07100

Novartis Investigative Site, Sassari

05100

Novartis Investigative Site, Terni

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY